Applications of (2R,4R)-4-Methylpiperidine-2-Carboxylic Acid in Industrial Manufacturing

As a direct manufacturer of (2R,4R)-4-Methylpiperidine-2-Carboxylic Acid, we supply this high-purity intermediate for use in tightly regulated sectors. All applications listed here represent observed and validated downstream uses, with details on compliance, formulation, process integration, and final product types based on real customer manufacturing requirements.

1. Chiral Pharmaceutical Intermediate for Neuroactive Drugs

This compound serves as a critical chiral building block for the synthesis of active pharmaceutical ingredients (APIs) targeting neurological disorders. Its asymmetric structure supports the synthesis of compounds with defined stereochemistry, meeting regulatory specifications in API production for CNS therapeutics. Manufacturers use this intermediate during the key amide coupling steps, ensuring enantiomeric purity in the final molecule necessary for targeted biological activity.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) monograph compliance for API intermediates
• US FDA 21 CFR Part 210/211 for cGMP requirements
• Chinese Pharmacopoeia API intermediate quality requirements

Typical usage ratio

• Employed in stoichiometric concentrations; typical range is 1.05–1.2 mol equivalents relative to target API intermediate, depending on reaction scale and subsequent purification requirements

Downstream process integration

• Introduced during asymmetric synthesis at the amide condensation stage, followed by in-process chiral resolution and subsequent coupling or cyclization reactions

Final product types

• Chiral pyrrolidine-based CNS drug actives
• Active intermediates for anti-Alzheimer’s medications
• APIs for epilepsy and neuroprotective treatments

2. Synthetic Intermediate for Peptide Drug Manufacturing

The compound functions as a protected amino acid analogue in the assembly of modified peptides. Its role lies in imparting conformational restriction to peptide sequences, enhancing biological activity and resistance to proteolytic degradation. Large-scale peptide synthesis facilities utilize the material during Fmoc- or Boc-based solid phase peptide synthesis (SPPS) protocols for specialty therapeutic peptides.

Industry compliance standards

• US FDA Guidance for Industry: Q11 Development and Manufacture of Drug Substances
• EU GMP Part II (ICH Q7) for pharmaceutical-grade peptide intermediates
• Japanese Pharmacopoeia technical requirements for modified amino acids
• ISO 9001 certified quality management systems for regulated peptide production

Typical usage ratio

• Used at 1.0 molar equivalent per installed residue position in peptide chain; excess levels up to 1.2 equivalent may be adopted to drive coupling reactions in longer sequences

Downstream process integration

• Incorporated during resin loading or chain elongation steps in SPPS, followed by cleavage and purification via HPLC to isolate the protected peptide

Final product types

• Stabilized therapeutic peptides
• Peptide-based injectable formulations
• Modified peptide hormone analogues

3. Intermediate for Agrochemical Synthesis (Chiral Herbicides)

Within the agrochemical sector, this molecule provides a stereochemically defined intermediate for the preparation of selective chiral herbicides. Agrochemical formulators introduce it in the construction of heterocyclic moieties, where its precise configuration enables high selectivity and enhanced biodegradation profiles, facilitating environmental regulatory acceptance of new herbicide active ingredients.

Industry compliance standards

• OECD Guidelines for the Testing of Chemicals – Synthesis intermediates (Section 1 and 3)
• EPA 40 CFR Part 169 (US) for pesticide chemical production and record keeping
• REACH Regulation (EC) No 1907/2006 – registration and safety data
• ISO 9001 for agrochemical manufacturing traceability

Typical usage ratio

• Common dosage levels range from 0.95 to 1.1 molar equivalent per cycle, adjusted for product yield optimization and downstream chiral purity requirements

Downstream process integration

• Employed at the cyclization or chiral functionalization stage of heterocyclic herbicide synthesis, followed by purification and active ingredient formulation

Final product types

• Selective post-emergence chiral herbicidal actives
• Custom-formulated crop protection products
• Pre-mix technical grade herbicide concentrates for further formulation

4. Precursor in Custom Chiral Ligand Production for Asymmetric Catalysis

Catalyst manufacturers use this compound as a precursor in crafting specialty chiral ligands required for asymmetric hydrogenation and other enantioselective transition metal-catalyzed transformations. Its fixed axial and center chirality provides essential features for ligand architectures that influence enantiomeric excess and turnover rates in downstream customer processes, particularly in pharmaceutical and fine chemical manufacturing.

Industry compliance standards

• ISO 17034:2016 for reference material producers
• GMP guidelines for catalyst components in API synthesis
• US FDA Q11 for starting materials in regulated drug synthesis
• Internal SOPs validated for fine chemical process inputs

Typical usage ratio

• Formulation typically requires 1.0 molar equivalent per ligand backbone formation; excess up to 1.15 equivalents may be used to increase chiral yield during batch synthesis

Downstream process integration

• Added at nucleophilic substitution or reductive amination stage, followed by downstream ligand-metal complexation and performance QC

Final product types

• Enantioselective hydrogenation catalyst ligands
• Chiral phosphine or diamine ligand platforms
• Custom ligand systems for pilot and commercial-scale asymmetric synthesis

5. Key Building Block for Pharmaceutical Impurity Standards

Reference standard manufacturers integrate this molecule into the targeted synthesis of specified impurities for regulatory submission, stability testing, and batch release protocols. Its chiral purity allows accurate simulation of synthetic or degradation pathways involved in API impurity profiling, which assists QC labs in developing validated analytical methods for major international regulatory filings.

Industry compliance standards

• ICH Q3A/B for Impurities in New Drug Substances and Products
• USP General Chapter <1086> for Impurity Reference Standards
• EDQM (European Directorate for the Quality of Medicines) guidance on impurity standards
• ISO/IEC 17025 for laboratory testing and calibration

Typical usage ratio

• Used through stoichiometric or slightly excess amounts (1.0–1.1 equivalents) depending on targeted impurity synthetic pathway and required batch size

Downstream process integration

• Enters during stereo-controlled side chain installation or ring closure, followed by purification and reference material certification

Final product types

• Pharmaceutical impurity reference materials
• Certified analytical standards for regulatory method validation
• Standardized impurity mixes for QC laboratories